THOUSAND OAKS, Calif., Oct. 1, 2025 — Amgen announced that its landmark VESALIUS-CV Phase 3 trial met primary endpoints in evaluating cardiovascular risk reduction for more than 12,000 patients without prior myocardial infarction or stroke. The study demonstrated that treatment significantly reduced major adverse cardiovascular events (MACE) in individuals at elevated risk, establishing new evidence in primary prevention strategies.
Science Significance
VESALIUS-CV represents one of the largest and most rigorous prevention trials in cardiovascular medicine. The trial showed that therapy targeting LDL-C reduction led to meaningful decreases in MACE, including heart attack, stroke, and cardiovascular death. This builds on decades of lipid science and underscores the role of proactive LDL-C lowering in protecting patients even before clinical cardiovascular events occur.
Regulatory Significance
The success of VESALIUS-CV paves the way for regulatory filings to expand indications of LDL-C lowering therapies into primary prevention populations. Positive results will provide agencies like the FDA and EMA with strong evidence to consider broader approvals, potentially transforming treatment guidelines for cardiovascular disease prevention.
Business Significance
Advertisement
Cardiovascular disease is the leading cause of global mortality, affecting more than 500 million people worldwide. Expanding indications for LDL-C lowering therapies into primary prevention could open a multi-billion-dollar commercial market. Amgen’s success in this trial strengthens its leadership in cardiometabolic health and bolsters confidence in its long-term pipeline strategy.
Patients’ Significance
For patients at risk of cardiovascular disease, these findings highlight the possibility of preventing the first major event—a heart attack or stroke—through earlier, more aggressive LDL-C control. The trial provides reassurance that effective therapies can protect patients long before irreversible damage occurs, improving survival and quality of life.
Policy Significance
The VESALIUS-CV trial emphasizes the need for policy frameworks that support preventive care. By expanding coverage and access to cholesterol-lowering therapies, healthcare systems can reduce long-term costs associated with hospitalizations, disability, and mortality from cardiovascular events. This trial may also drive updates in global cardiovascular prevention guidelines.
The VESALIUS-CV Phase 3 success marks a historic milestone in cardiovascular medicine. With compelling evidence supporting early intervention, the results strengthen regulatory, business, and patient-focused momentum for preventive strategies. Amgen’s findings may reshape how healthcare systems worldwide approach heart disease prevention, offering new hope for millions at risk.
Source: Amgen press release
